Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and ...
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment ...
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life ...
Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed ...
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as ...
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results